Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: at-13148 | 0.80 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 430 | 0.82 |
| pathways Reactome | 10 pathways; mostly iron and oxidative stress | 0.80 |
No case: the score is under the bar. Receipt 4424
Sealed predictions
- MAPKAPK2 in dopamine neurons, braak-0.82 (p 0.007) → -0.63 (p 0.068)receipt 4431
Swarm cases
receipt 4431: MAPKAPK2 in dopamine neurons, braak
- power
- full sample -0.70 (p 0.0011, n 18), 95% CI -0.88 to -0.35. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.70 (p 0.0013, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.82 (p 3.0e-5, n 18). not the mix.
- skeptic
- leave-one-out range -0.84 to -0.67, sign flips 0; without severely affected donors -0.70 (p 0.0011, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MAPKAPK2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts